On this page of StockholderLetter.com we present the latest annual shareholder letter from Quoin Pharmaceuticals, Ltd. — ticker symbol QNRX. Reading current and past QNRX letters to shareholders can bring important insights into the investment thesis.
2024 Annual Report to Shareholders Quoin Pharmaceuticals Ltd. Effective April 9, 2025, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing one (1) ordinary share to 1 ADS representing thirty-five (35) ordinary shares, which resulted in a 1 for 35 reverse split of the issued and outstanding ADSs (the Reverse Split ). Our Annual Report on Form 10-K for the year ended December 31, 2024 (the Annual Report ) was filed on March 13, 2025 and as such, the Annual Report (including the financial statements included therein) does not reflect the Reverse Split.
 • shareholder letter icon 7/17/2025 Letter Continued (Full PDF)
 • stockholder letter icon 9/12/2023 QNRX Stockholder Letter
 • stockholder letter icon 10/24/2024 QNRX Stockholder Letter
 • Benford's Law Stocks icon QNRX Benford's Law Stock Score = 84


QNRX Shareholder/Stockholder Letter Transcript:

2024
Annual Report
to Shareholders
Quoin Pharmaceuticals Ltd.
Effective April 9, 2025, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing one (1) ordinary
share to 1 ADS representing thirty-five (35) ordinary shares, which resulted in a 1 for 35 reverse split of the issued and
outstanding ADSs (the    Reverse Split   ). Our Annual Report on Form 10-K for the year ended December 31, 2024 (the
   Annual Report   ) was filed on March 13, 2025 and as such, the Annual Report (including the financial statements included
therein) does not reflect the Reverse Split.



shareholder letter icon 7/17/2025 Letter Continued (Full PDF)
 

QNRX Stockholder/Shareholder Letter (Quoin Pharmaceuticals, Ltd.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.